Merck did not immediately respond to Reuters' request for a comment, while Eyebiotech declined to comment. Eyebiotech is a clinical stage opthalmology company, with operations in the U.S. and the ...

Investing.com-- Merck&Company Inc (NYSE:MRK) is close to entering a $1.3 billion deal to buy Eyebiotech, granting the pharmaceutical giant entry into the rapidly growing eyecare market, the Wall ...

(Reuters) -Merck on Wednesday agreed to buy privately held biotech EyeBio for as much as $3 billion, as it looks to diversify its portfolio of experimental drugs with treatments for eye diseases.

Merck & Co., Inc. MRK is reportedly on the verge of acquiring EyeBio, an eye drug company, for a sum of $1.3 billion.This acquisition is expected to significantly expand Merck’s presence in the ...

(Reuters) -Merck & Co is nearing a $1.3 billion cash deal to buy ophthalmology biotechnology company Eyebiotech in an agreement that could see an additional $1.7 billion in milestone payments, the ...

The drugmaker agreed to pay $1.3 billion in cash and another $1.7 billion in future milestone-based payments for EyeBio, and will gain access to its retinal disease drug Restoret as part of the deal.

London: Merck & Co is nearing a $1.3 billion cash deal to buy ophthalmology biotechnology company Eyebiotech in an agreement that could see an additional $1.7 billion in milestone payments, the ...